This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Low Back Pain. Measurement will happen over the course of 1 year.
This trial requires 230 total participants across 1 different treatment groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
around 26 million Americans experience low [back pain](https://www.withpower.com/clinical-trials/back-pain) each year. Those who do so tend to have recurrent episodes of pain. About 20% of the American population suffers from back pain a year and over two million every year seek treatment. More than half a million Americans are hospitalized each year with low back disease.
LBP is common and is frequently treated. There are a variety of treatments for LBP currently, but the majority use conventional treatments and/or physical therapies. The efficacy of conservative treatment is not proven and there are numerous risks involved in conventional treatments. For physical therapies, high quality trials with evidence-based guidelines are lacking.
Specific signs that are suggestive of low back pain should be considered when seeking medical help in patients with chronic low back pain. The clinical examination should be the leading tool for diagnosing the cause of lumbago and is also a valid measure to identify those patients who should be offered alternative diagnostic tests.
Unfortunately, most current treatments appear to be only moderately efficacious (e.g. medication, psychotherapy and exercise) for pain relief in low back pain. Further research should be directed to identify a novel, multi-dimensional "treatment" for chronic low back pain that effectively reduces pain and improves function.
Most LBP cases are chronic in nature and cause high levels of pain and disability in affected patients. The duration, intensity, and frequency of the LBP episodes have shown to be an important predictor of the severity of chronic LBP in patients. It is worth emphasizing that the management of LBP is not just focused on relieving pain but also addressing the physical and family issues. So far, we have no way to predict which patients are going to experience LBP pain long term so, the future research should focus on finding the best way to predict the long term progression of LBP.
A diagnosis of [back pain](https://www.withpower.com/clinical-trials/back-pain) can be difficult due to the wide range of causes. There is no single definitive cause of lumbago which is the most common cause of low back pain. Therefore, it is vital that a clear explanation of the cause of the pain is ascertained before the diagnosis of lumbago is made or an accurate prognosis is made.
The most commonly used treatments are nonsteroidal anti-inflammatory drugs, manual therapy, and narcotic analgesics. All are commonly used in combination with other treatments and are effective in improving quality of life in LBP patients. The combination of treatment is the most effective way to decrease pain and to improve quality of life; it involves nonsteroidal anti-inflammatory drugs, manual therapy, and narcotic analgesics.
In a recent study, findings of this sample of older women suggest that therapists, educators, and other caregivers may wish to address the possibility that some people with chronic pain have a nociceptive component to their symptom experience. Treating this component in patients may be a nalog tool that contributes to patient engagement and outcomes.
Results from a recent clinical trial suggests that side effects of treatment in lumbar degenerative disease may vary for different spine surgeons and from one patient to the next. It also supports the inclusion of all possible side effects in the medical record in order to prevent bias in treatment choice and assist with post-treatment patient decision-making. It further indicates that there is a need for a more standardized method to classify and report side effects.
Most of the physicians who are interested in participating in a clinical trial for LBP do not consider any major barriers to participation. Thus, the time and inconvenience incurred would be low and would not be a major barrier to study participation. The cost of participation would not affect participation decision. Furthermore, most of the physicians would want a higher threshold for prescribing NSAIDs, suggesting that participation in such trials might not be a big barrier to study drug prescribing.
[Treatment of lumbar spine pain following cervical disk herniation is generally safe and well-tolerated.] This is particularly true for women and younger patients. The evidence supports caution regarding the safety of using epidural corticosteroids or epidural local anesthetics for treatment of long-term lumbar spine pain or disability following cervical disk herniation.
The last 10 years has brought important improvements in the treatments for LBP and pain. However, the current understanding of how LBP and pain work to cause damage to the body seems to be limited. Clinical trials for LBP and pain treatments that focus on the brain are likely to have the best results. [Determining Treatment Effects of Back Pain (http://www.thedie.org/news/2011/07/determining-treatment-effects-of-back-pain) The NIH Clinical Centers has established seven Clinical Centers (Limbic LBP Initiative), and they are [going to study low back pain more systematically.